DNA replication licensing is associated with resistance to CDK4/6 inhibitors in ER-positive breast cancer

被引：0
|
作者：
Nanda, Sarmistha
Shea, Martin J.
Schiff, Rachel
Osborne, C. Kent
Rimawi, Mothaffar
Fu, Xiaoyong
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 05期
关键词：
D O I：
10.1158/1538-7445.SABCS22-P2-03-10
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P2-03-10
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER plus breast cancer
    Formisano, Luigi
    Lu, Yao
    Servetto, Alberto
    Hanker, Ariella B.
    Jansen, Valerie M.
    Bauer, Joshua A.
    Sudhan, Dhivya R.
    Guerrero-Zotano, Angel L.
    Croessmann, Sarah
    Guo, Yan
    Ericsson, Paula Gonzalez
    Lee, Kyung-Min
    Nixon, Mellissa J.
    Schwarz, Luis J.
    Sanders, Melinda E.
    Dugger, Teresa C.
    Cruz, Marcelo Rocha
    Behdad, Amir
    Cristofanilli, Massimo
    Bardia, Aditya
    O'Shaughnessy, Joyce
    Nagy, Rebecca J.
    Lanman, Richard B.
    Solovieff, Nadia
    He, Wei
    Miller, Michelle
    Su, Fei
    Shyr, Yu
    Mayer, Ingrid A.
    Balko, Justin M.
    Arteaga, Carlos L.
    NATURE COMMUNICATIONS, 2019, 10 (1)
  • [22] IMMUNOLOGICAL MECHANISMS OF RESISTANCE TO CDK4/CDK6 INHIBITORS IN BREAST CANCER
    Petroni, Giulia
    Gouin, Kenneth
    Martinez, Aitziber Buque
    Knott, Simon
    Formenti, Silvia
    Galluzzi, Lorenzo
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A763 - A763
  • [23] Mechanisms of resistance to CDK4/6 inhibition in ER plus breast cancer
    Lee, N. V.
    Eisele, K. J.
    Chionis, J.
    Yuan, J.
    Zhu, Z.
    Liu, C.
    Li, D.
    Olson, P. A.
    Fantin, V.
    Arndt, K. T.
    Shields, D. J.
    VanArsdale, T. L.
    CANCER RESEARCH, 2016, 76
  • [24] Acquired CDK6 amplification promotes breast cancer resistance to CDK4/6 inhibitors and loss of ER signaling and dependence
    C Yang
    Z Li
    T Bhatt
    M Dickler
    D Giri
    M Scaltriti
    J Baselga
    N Rosen
    S Chandarlapaty
    Oncogene, 2017, 36 : 2255 - 2264
  • [25] CDK4/6 inhibitors in HER2-positive breast cancer
    Corona, Silvia Paola
    Ravelli, Andrea
    Cretella, Daniele
    Cappelletti, Maria Rosa
    Zanotti, Laura
    Dester, Martina
    Gobbi, Angela
    Petronini, Pier Giorgio
    Generali, Daniele
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2017, 112 : 208 - 214
  • [26] Overcoming resistance to inhibitors of CDK4/6 and BET in estrogen receptor-positive breast cancer
    Cosin, Marc
    Tian, Tian
    Oliveros, Winona
    Kharenko, Olesya A.
    van der Horst, Edward H.
    Patel, Reena G.
    Calosing, Cyrus
    Campeau, Eric
    Jahagirdar, Ravi
    Lakhotia, Sanjay
    Mele, Marta
    Palafox, Marta
    Arribas, Joaquin
    Oliveira, Mafalda
    Saura, Cristina
    Serra, Violeta
    Peiro, Sandra
    CANCER RESEARCH, 2020, 80 (16)
  • [27] Acquired CDK6 amplification promotes breast cancer resistance to CDK4/6 inhibitors and loss of ER signaling and dependence
    Yang, C.
    Li, Z.
    Bhatt, T.
    Dickler, M.
    Giri, D.
    Scaltriti, M.
    Baselga, J.
    Rosen, N.
    Chandarlapaty, S.
    ONCOGENE, 2017, 36 (16) : 2255 - 2264
  • [28] CDK4/6 inhibitors in HR-positive breast cancer immunotherapy
    Shen, Mimi
    Ma, Zhiyuan
    Zhu, Jiaxing
    Wen, Guorong
    Jin, Hai
    An, Jiaxing
    Tuo, Biguang
    Liu, Xuemei
    Li, Taolang
    BIOORGANIC CHEMISTRY, 2025, 154
  • [29] The Role of CDK4/6 Inhibitors in Breast Cancer
    Murphy, Conleth G.
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2019, 20 (06)
  • [30] MDM2 inhibition in combination with endocrine therapy and CDK4/6 inhibition for the treatment of ER-positive breast cancer
    Portman, Neil
    Milioli, Heloisa H.
    Alexandrou, Sarah
    Coulson, Rhiannon
    Yong, Aliza
    Fernandez, Kristine J.
    Chia, Kee Ming
    Halilovic, Ensar
    Segara, Davendra
    Parker, Andrew
    Haupt, Sue
    Haupt, Ygal
    Tilley, Wayne D.
    Swarbrick, Alex
    Caldon, C. Elizabeth
    Lim, Elgene
    BREAST CANCER RESEARCH, 2020, 22 (01)
12345